AVEVA (LSE: AVV) and Filtrona (LSE: FLTR) are flying today
The FTSE 100 (UKX) is creeping higher today, up 32 points to 5,825 points at the time of writing -- so perhaps there's fog in the Channel and we're cut off from Europe. We're still a little way off the year's high-water mark of 5,989 points, but surely it can't be long before that's beaten now, can it?
Obviously, individual companies can do better or worse than the index every day. Here are three names from the various FTSE indices that look set to beat the market today:
AVEVA Group (LSE: AVV) enjoyed a 49p (2.5%) boost, taking the shares up to 2,039p, after releasing a trading update that told of positive progress in the first half of the year. The firm, which provides engineering IT products and consultancy services, announced good revenue growth over the same period last year, principally from its work in the oil and gas sector.
The shares are now up more than 40% over the past 12 months, but they've reached a slightly heady forward price to earnings (P/E) ratio of 25. The long-term average P/E for the FTSE is around 14.
An interim update from Filtrona (LSE: FLTR) led to a 27p (5.3%) jump in the share price to 537p today. The firm, which supplies speciality plastics, fibres and foams, told us of 'strong momentum' in its third quarter, and that it expects to achieve its growth targets for the full year.
Revenue at the Q3 stage was 23% ahead of the previous year, at current exchange rates, with like-for-like growth at 10%. The shares are up 50% during the past year, and look set to deliver a dividend of around 2.5%, forecast to rise to nearer 3% by December 2013.
If rising dividends are what you want, you could do worse than check out ace investor Neil Woodford's strategy. The Motley Fool report, "8 Shares Held By Britain's Super Investor", takes a look at some of his major holdings. Click here to get your free copy, while it's still available.
Optos (LSE: OPTS) gained 14p (7%) to 211p on the back of a trading update that revealed a performance ahead of forecasts. The retinal imaging technologist now expects revenues for the full year to September to exceed $190 million, helped by an 11% increase to its customer base.
This share has had an erratic ride this year, and forecasts before today suggested a 40% fall in earnings this year, with a recovery expected next year, to put the shares on a forward P/E of 16. Those profit expectations will presumably be revised upwards now.
High-technology growth shares can be one step on the ladder to making your first million from investing in shares. You might not think it's possible, but many long term investors have achieved it. This free Motley Fool report tells you how.
Further Motley Fool investment opportunities:
> Alan Oscroft does not own any shares mentioned in this article.